We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Doqit offers a solution for managing life admin tasks, helping you organize important information, set action dates, and receive timely reminders, ultimately streamlining tasks like insurance renewals and warranties to reduce unnecessary expenses and simplify your life. It provides secure storage and easy access for vital information, transitioning from chaos to simplicity.  Security is also a priority for Doqit. The platform ensures that your sensitive information is stored securely, giving you peace of mind knowing that you can access your important documents and data whenever you need them, all within a few clicks.
days to go: Extended investment: £87,500
Morgan Goodwin is a UK-based company that pioneers the Combined Trading Platform (CTP) category, offering a comprehensive online platform for small businesses engaged in physical goods trading, along with specialized software development services, and a broad-spectrum business consultancy approach aimed at enhancing growth, efficiency, and technological advancement.
days to go: Stretch investment: £788,519
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
UTU is a company dedicated to building the trust infrastructure for the evolving web 3.0. They aim to facilitate safer and more reliable interactions between users and platforms by utilizing a decentralized reputation and reviews protocol. This protocol involves a non-tradable reputation token (UTT) that users can stake to endorse others, leading to positive outcomes. UTU's focus initially lies in Web3 and DeFi apps, where they provide AI-powered tools to curate trust signals and help users engage confidently in various online activities. They offer a range of products, including the UTU Trust Token, Browser Extension, and Trust API/SDK, all aimed at enhancing trust and security in digital interactions.
days to go: Extended investment: £150,000
Intellibonds is an AI/Human collaborative investment platform for fixed income institutional investors. The platform analyses the users' objectives and renders intuitive financial analytical data for the user to make the correct investment decision with the click of a button. The modular AI-enabled assistants (virtual workforce) support workflow and augment decision-making of credit analysts, portfolio managers and traders (in development). In 2019, IntelliBonds joined Fintech Sandbox accelerator and Microsoft programme for startups. In 2020, the company made data partnerships with Refinitiv, S&P Global Ratings and BondRadar, as well as, formed a strategic partnership with University College London (UCL). The company will launch two modules; a Virtual Credit Assist (VCA) and Virtual Portfolio Assist (VPA) to further simplify the process of financial investments. It will use £225,000 of the investment for product development, £50,000 for distribution channels, and £25,000 for patents, trademarks and other legal/advisory fees.

Pitch Rated

80%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £383,275
Ticketpass is a ticketing platform that is set to disrupt the traditional ticketing industry with an ethical approach by donating to charity every time a ticket is sold. This 'Tech for Good' company aims to create a fair platform that uses ticketing to create a positive impact, allowing anyone to enhance their events for better social impact at no extra cost. Ticketpass won the Warwick Startup Venture Cup in 2016. It also launched its iOS and Android check-in apps in 2018. In 2019, the official launch of Ticketpass was featured by National Industry Media and Forbes. The company will allocate 56% of the funds to team/tech development, 17% to new hires, 10% to marketing and the remaining 17% to Office & Operations.

Pitch Rated

78%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £282,667
HairFare is an end-to-end hair and beauty chair rental platform that connects beauty professionals to salons, studios and barbershops across the UK. It asserts that the hair and beauty industry was worth £10 billion in 2018 and is set to increase. HairFare aims to be a contender in this segment. HairFare asserts that it has expanded to five cities within the UK with no marketing budget. The platform has featured in media platforms including The Barber Magazine, Islington Gazette, Startups of London, Business Daily, ITProPortal, ExBulletin, Compsmag, and LinkedIn News, to name a few. It will use 40% of the investment for creating its proprietary app, 40% towards marketing to increase the number of business owners and beauty professionals on the platform, 10% towards setting up its merchandise line, and 10% towards establishing the HairFare Academy.

Pitch Rated

76%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £57,736
Hypha is an innovation intelligence platform. The company combines ontology mapping and graph processing to connect and leverage knowledge such that it is contextually aligned to an enterprise’s unique structure, systems, processes, and strategic objectives. Hypha deploys features on its platform such as clustering boards, browser extension tools, custom branding, and cloud-based deployment to help organisations achieve growth and profitability. The company has onboarded multiple entities on its integration roadmap, such as Miro, Microsoft Teams, Office 365, GSuite, and Dropbox, to name a few. The company has secured 6 enterprise clients worldwide, with IKEA as one of their illustrious clients. It will use 80% of the investment for product development and 20% for sales and marketing.

Pitch Rated

75%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £222,100
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph